Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

DOI: 10.1056/nejmoa2033617
New England Journal of Medicine, 2021, 385, 1280-1291.

#	Paper	IF	Citations
124	Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. *New England Journal of Medicine*, **2021**, 385, 1302-1315	59.2	16
123	Ozanimod is efficacious in ulcerative colitis. **2021**, 18, 748		
122	Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. **2021**,		12
121	Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities. **2021**,		
120	Essential updates 2020/2021: Colorectal diseases (benign)Current topics in the surgical and medical treatment of benign colorectal diseases.		0
119	Ozanimod for Ulcerative Colitis.. *New England Journal of Medicine*, **2022**, 386, 194	59.2	2
118	Targeting Chronic Inflammation of the Digestive System in Cancer Prevention: Modulators of the Bioactive Sphingolipid Sphingosine-1-Phosphate Pathway.. **2022**, 14,		3
117	Appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis.		
116	The Role of the Lymphatic System in the Pathogenesis and Treatment of Inflammatory Bowel Disease.. **2022**, 23,		2
115	Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease.. **2022**,		2
114	Review: emerging drug therapies in inflammatory bowel disease.. **2022**,		3
113	Hypertensive Emergency After Initiating Ozanimod: A Case Report.. **2022**,		
112	Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art.. **2022**, 11,		0
111	Gut Microbiota, Macrophages and Diet: An Intriguing New Triangle in Intestinal Fibrosis.. **2022**, 10,		1
110	Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases.. **2022**, 11,		0
109	[Living guideline on ulcerative colitis].. **2022**, 93, 261		
108	Colitis ulcerosa: Ozanimod eine vielversprechende Therapieoption. **2022**, 147, 221-222		

107	[Inflammatory bowel diseases - therapy update 2022].. **2022**, 147, 295-300	
106	Ozanimod in the Treatment of Ulcerative Colitis: Initial Real World Data from A Large Tertiary Center.. **2022**,	0
105	Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.. **2021**,	5
104	Advances in understanding and examining lymphatic function: relevance for understanding autoimmunity.. **2021**, 34,	1
103	The sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis: a unique therapeutic target in inflammatory bowel disease.. **2021**,	5
102	Colitis ulcerosa: Ozanimod eine vielversprechende Therapieoption. **2021**, 17, 312-312	
101	Treatment of Inflammatory Bowel Disease: A Comprehensive Review.. **2021**, 8, 765474	9
100	Role of microRNAs in the Pathophysiology of Ulcerative Colitis. **2021**, 1, 558-573	
99	Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?. **2022**, 10,	
98	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel.. **2022**,	0
97	An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis.. **2022**, 11,	0
96	Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.	
95	Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease. Authors' reply.. **2022**, 55, 1360	
94	Emerging therapies for ulcerative colitis.. **2022**, 1-12	2
93	An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.. **2022**,	0
92	Is it time to include older adults in inflammatory bowel disease trials? A call for action. **2022**, 3, e356-e366	1
91	Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. **2022**,	12
90	An Overview of Tissue-Resident Memory T Cells in the Intestine: From Physiological Functions to Pathological Mechanisms. 13,	0

89	Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis.	1
88	Discovery of In Vivo Active Sphingosine-1-phosphate Transporter (Spns2) Inhibitors.	0
87	Stellungnahme der DGVS zur Nutzenbewertung des GBA zum Wirkstoff Filgotinib (Anwendungsgebiet: Colitis Ulcerosa, vorbehandelte Patient*innen). **2022**, 60, 1047-1050	
86	Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials.	
85	Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. 9,	0
84	Critical roles of G protein-coupled receptors in regulating intestinal homeostasis and inflammatory bowel disease.	0
83	IBD therapeutics: what is in the pipeline?. **2022**, 13, e35-e43	0
82	Mechanism-driven strategies for prevention of rheumatoid arthritis.	1
81	Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives. **2022**, 11, 2058	1
80	Integrating new and emerging therapies into inflammatory bowel disease clinical practice. **2022**, 38, 328-336	1
79	Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis. **2022**, 9, e00832	0
78	Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine. **2022**, 10, 1735	0
77	Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD). **2022**, 11, 4374	0
76	Contribution of circulatory cells to asthma exacerbations and lung tissue-resident CD4 T cell memory. 13,	0
75	Safety and tolerability of spesolimab in patients with ulcerative colitis. 1-11	0
74	Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets. **2022**, 82, 1151-1163	
73	Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.	
72	Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study. **2022**,	0

71	Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation.	3
70	Ozanimod: A Review in Ulcerative Colitis.	0
69	Current and future aspects of IBD research and treatment: The 2022 perspective. 1,	
68	Efficacy and safety of ozanimod for ulcerative colitis (review). **2022**, 21, 119-129	0
67	The Memory T Cell Communication Web In Context with Gastrointestinal Disorders How Memory T Cells Affect Their Surroundings and How They Are Influenced by It. **2022**, 11, 2780	0
66	Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing. **2022**, 15, 1080	1
65	Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks.	0
64	A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application. Volume 18, 913-927	1
63	How sphingolipids affect T cells in the resolution of inflammation. 13,	2
62	Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis.	0
61	Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices. **2022**, 11, 5267	0
60	Landscape of new drugs and targets in inflammatory bowel disease.	1
59	Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.	0
58	Development of a Core Outcome Set for Real-World Data in Inflammatory Bowel Disease: A European Crohn and Colitis Organisation (ECCO) Position Paper.	0
57	Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program. **2022**, 106958	0
56	Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies.	0
55	Questions to consider when caring for patients with ulcerative colitis.	0
54	Perspectivas actuales sobre la enfermedad inflamatoria intestinal pedi rica con un enfoque en el manejo en el per odo de transici . ¿Qu debemos considerar?. **2022**,	0

53	Integrated Metabonomics and Network Pharmacology to Reveal the Action Mechanism Effect of Shaoyao Decoction on Ulcerative Colitis. Volume 16, 3739-3776	0
52	Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update. 1,	0
51	Mucosal and plasma metabolomes in new-onset paediatric inflammatory bowel disease: correlations with disease characteristics and plasma inflammation protein markers.	1
50	Esophageal lichen planus: Current knowledge, challenges and future perspectives. 28, 5893-5909	0
49	Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond.	0
48	Polyphenols and inflammatory bowel disease: Natural products with therapeutic effects?. 1-24	1
47	Emerging drugs for the treatment of inflammatory bowel disease.	0
46	A review of the therapeutic management of ulcerative colitis. **2022**, 15, 175628482211381	0
45	In vitro assessment of the binding and functional reponses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors. **2022**, 175442	0
44	Bile acids as inflammatory mediators and modulators of intestinal permeability. 13,	0
43	Controlling in and out □the future of interfering with immune cell trafficking in inflammatory bowel disease. 1-13	0
42	Fast recapture of response with ozanimod after withdrawal in UC.	0
41	Medical Treatment Options for Ulcerative Colitis.	0
40	Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease. 28, 6888-6899	0
39	An update on efficacy and safety comparison of biologics in treatment of inflammatory bowel disease targeting TNF-□interleukins, leukocyte trafficking, Janus-kinase, and sphingosine-1-phosphate receptor. 1-25	0
38	Letter: ozanimod and latent tuberculosis□uthors' reply. **2023**, 57, 355-356	0
37	Letter: Ozanimod and latent tuberculosis. **2023**, 57, 353-354	1
36	Unveiling the biological role of sphingosine-1-phosphate receptor modulators in inflammatory bowel diseases. 29, 110-125	0

35	Therapeutic Management of Adults with Inflammatory Bowel Disease and Malignancies: A Clinical Challenge. **2023**, 15, 542	0
34	Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies. **2023**, 158, 114174	0
33	S730 Ozanimod Is an Efficacious Oral Therapy After 5-ASA Failure in Immunomodulator- and Biologic-Naive Patients With Ulcerative Colitis: Post Hoc Analysis From True North. **2022**, 117, e512-e513	0
32	Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease.	1
31	Is hypertension an extra-intestinal manifestation of inflammatory bowel disease?. **2023**, 11, 7-8	0
30	Therapieupdate 2022: Colitis´ulcerosa. **2023**, 18, 54-63	0
29	Conventional treatment and new drugs. **2023**, 47-69	0
28	The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis. **2023**, 401, 1132-1133	0
27	2-Aminobenzoxazole Derivatives as Potent Inhibitors of the Sphingosine-1-Phosphate Transporter Spinster Homolog 2 (Spns2).	0
26	The oft-overlooked cardiovascular complications of inflammatory bowel disease. **2023**, 19, 375-391	0
25	Magen/Darm- und Lebererkrankungen. **2022**, 303-328	0
24	Sacral Nerve Stimulation Alleviates Intestinal Inflammation Through Regulating the Autophagy of Macrophages and Activating the Inflammasome Mediated by a Cholinergic Antiinflammatory Pathway in Colitis Rats. **2023**,	0
23	S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights. **2023**, 250, 115182	0
22	Ozanimod Attenuates Human Cerebrovascular Endothelial Derived MMP-9 Activity and Preserves Barrier Properties Following In Vitro Acute Ischemic Injury.	0
21	Ozanimod-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis. **2023**, 10, e00929	0
20	Etrasimod for the treatment of ulcerative colitis. **2023**, 15, 311-321	0
19	Recruitment and residence of intestinal T cells lessons for therapy in IBD.	0
18	Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows.	0

17	Treatment update 2022: ulcerative colitis. **2023**, 26, 58-65	0
16	Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. **2023**, 401, 1159-1171	0
15	Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review. **2023**, 11, 747	0
14	Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone. **2023**, 10, e00955	0
13	Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials. **2023**, 28, 27-42	0
12	Ulcerative colitis (K51), adults. **2023**, 22, 10-44	0
11	Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis. **2023**, 16, 175628482311582	0
10	The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom. 1-9	0
9	A critical review of ustekinumab for the treatment of active ulcerative colitis in adults. 1-18	0
8	Current perspectives on pediatric inflammatory bowel disease focusing on transitional care management. What should we consider?. **2023**, 46, 139-147	0
7	Mise □jour sur le traitement m□dicamenteux de la colite ulc□euse. **2023**, 4, 19-26	0
6	Repurposing drugs against Alzheimer□s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?.	0
5	Is there an optimal sequence of biologic therapies for inflammatory bowel disease?. **2023**, 16, 175628482311594	0
4	Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.	0
3	Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy. **2023**, 15, 2389	0
2	Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany. **2023**, 38,	0
1	The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease.	0